Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and.

Slides:

Advertisements

Similar presentations

Implicaciones clínicas de los subtipos intrínsecos de cáncer de mama

Advertisements

Triple-Negative Breast Cancer

Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.

Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.

Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR.

Figure 1 The heterogenous landscape of triple-negative breast cancer

Volume 389, Issue 10087, Pages (June 2017)

TRIPLE NEGATIVE BREAST CANCER (TNBC) & ETHNIC MINORITIES

Fig. 2. Kaplan-Meier curves for survival in each breast cancer molecular subtype. Radiologic assessment in triple-negative breast cancer (A), HER2-positive.

Nurdianah HF, Nizuwan A, Muhamad Yusri M

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

Figure 2. DNA methylation mediated MORT gene silencing is linked to luminal, receptor positive breast cancers. (A) MORT expression level plotted versus.

Transcriptional heterogeneity of breast cancer subtypes,

Luminal A normal-like Figure S12: KNN graph analysis showed that the cancer data consists of a series of connected, bifurcating clusters. luminal B normal.

IOV – Istituto Oncologico Veneto I.R.C.C.S.

Hallett, et al., - Supplementary Figure 1

Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors Anita Muthukaruppan, Annette Lasham,

Table (1):Relation between lymph node and molecular subtypes.

Genotype-Phenotype Classification of Triple Negative Breast Cancers (TNBC) in Women of African Descent Using the PAM50 NanoString Platform and Genomic.

IHC-breast cancer subtypes of invasive ductal carcinoma with predominant intraductal component as an insignificant prognostic factor: A register-based.

Figure S1. DCYTB expression is higher in ER+ than ER- patients

Figure 1 Comparison of tumor size at time of excision between axillary node-negative, axillary node-positive, and distant metastasis subgroups of basal-like.

High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.

سرطان الثدي Breast Cancer

Nat. Rev. Urol. doi: /nrurol

A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer Gen Wang, Xiaosong.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis Diana Ramirez-Ardila, A. Mieke Timmermans,

Human triple‐negative breast cancers (TNBC) express WNT10B, show active Wnt signalling and have high proliferation, and WNT10B has clinical relevance and.

Tumor intrinsic subtype is reflected in cancer-adjacent tissue.

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Figure 3 Examples of gene expression heterogeneity

JNK signature in breast cancer cells is linked to ECM, stem cell, and wound healing gene networks and is enriched in basal‐like breast cancer JNK signature.

Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).

Volume 17, Issue 8, Pages (November 2016)

Relative quantitation of phosphopeptides from conditioned media from subtype specific breast cancer cell lines. Relative quantitation of phosphopeptides.

Overview of the complex interactions among molecular classifications of TNBC based on genomic, transcriptomic, proteomic, epigenomic, and immune characterization.

Triple‐negative human breast cancers specifically express high levels of nuclear HMGA2, whose expression has clinical relevance and predicts recurrence‐free.

Quality Assurance of RNA Expression Profiling in Clinical Laboratories

Volume 10, Issue 6, Pages (December 2006)

Down-regulation of LATS1 promotes the formation of tumors enriched in basal-like features. Down-regulation of LATS1 promotes the formation of tumors enriched.

HER-2/neu mRNA detection by gene expression profiling

Derivation and application of cancer‐specific epithelial‐mesenchymal transition (EMT) signature A six‐step scheme illustrating the generation of a cancer‐specific.

ADAM8 is overexpressed in human breast cancer AADAM8 mRNA expression in samples from breast tumor and normal breast tissue was analyzed using the Oncomine.

LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.

Breast Cancer Subtype Identification Using RNA-Seq Data

(A) Distribution of LATS2 mRNA expression levels in different breast cancer subtypes (PAM50, METABTIC dataset); ***P-value < 0.001, t test comparing lumB.

Correlation between Pten/p53 status and AKT pathway activity in BC and effect on clinical outcome Box plot for p53‐pathway activity in p53 wild‐type and.

NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T

Optoacoustic Imaging and Gray-Scale US Features of Breast Cancers: Correlation with Molecular Subtypes Total external optoacoustic US feature scores of.

Fig. 2 LYM attractor metagene.

Weiyang Lou, Bisha Ding, Weimin Fan Molecular Therapy - Oncolytics

Prof Matt Smalley, Director

Reduced BAI1 expression is associated with breast cancer patient survival. Reduced BAI1 expression is associated with breast cancer patient survival. A,

Differential methylation between AA and EA cases among breast cancer subtypes. Differential methylation between AA and EA cases among breast cancer subtypes.

M-Wnt and E-Wnt cells cluster tightly with claudin-low and basal-like breast tumors, respectively, by microarray analysis. M-Wnt and E-Wnt cells cluster.

Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.

EN1 expression in breast cancer and clinical outcome.

SAF-1 expression in clinical breast cancer tissues.

ORs estimates for ER breast cancer subtypes in postmenopausal women ccording to tertiles of sex steroid hormone and SHBG levels. ORs estimates for ER breast.

Clustering analysis of DTC-associated genes.

MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients treated with tamoxifen. MYC–HOXB7–HER2 predicts clinical outcome in breast cancer patients.

Frequently mutated genes in colorectal cancer.

Genomic determinants of response to cytotoxic chemotherapy.

Volume 28, Issue 3, Pages e7 (July 2019)

MYC and LYN are coexpressed and have interdependent clinical outcomes.

PTEN genotype frequently dictates PTEN expression status, but evidence of heterogeneous staining implies polyclonality within some ovarian tumors. PTEN.

Subtype classification of breast functional screening results.

Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.

Presentation transcript:

Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. Distribution of intrinsic subtypes among TNBC and distribution of TNBC among basal-like breast cancer. A, Comparison of distribution of intrinsic subtypes defined by PAM50 and PAM50 + claudin-low in The Cancer Genome Atlas (TCGA) and METABRIC data sets in TNBC. TNBC was defined as clinical ER-, PR-, and HER2-negative testing per IHC. In TCGA, 88 TNBC samples had available PAM50 data. The distribution of intrinsic subtypes was basal-like (86%), HER2-enriched (6%), luminal A (5%), luminal B (1%), and normal-like (2%). In METABRIC, 320 TNBC samples had available intrinsic subtype data. When including claudin-low in the PAM50 predictor, the distribution of subtypes was basal-like (49%), claudin-low (37%), HER2-enriched (9%), normal-like (4%), luminal A (1%), and luminal B (0%). When excluding the 119 samples with claudin-low subtype, the distribution of subtypes was basal-like (78%), HER2-enriched (15%), normal-like (5%), luminal A (2%), and luminal B (0%). B, Comparison of distribution of breast cancer subtype according to receptor status defined by IHC in TCGA and METABRIC data sets in basal-like breast cancer. Of 98 basal-like breast cancers in TCGA, 78% were TNBC per IHC. Of 209 basal-like breast cancers (PAM50 + claudin-low classifier) in METABRIC, 75% were TNBC. Figures generated by reanalysis of publicly available studies (refs. 22, 36, 37) using cBioPortal (refs. 150, 151). Ana C. Garrido-Castro et al. Cancer Discov 2019;9:176-198 ©2019 by American Association for Cancer Research